Italia markets closed

Dow Jones
38.704,41
+28,73(+0,07%)
Nasdaq
16.259,56
+103,23(+0,64%)
Nikkei 225
38.236,07
-38,03(-0,10%)
EUR/USD
1,0776
+0,0009(+0,09%)
Bitcoin EUR
59.046,64
-826,88(-1,38%)
CMC Crypto 200
1.369,56
+56,93(+4,34%)

Johnson & Johnson (JNJD.XC)

Cboe UK - Cboe UK Prezzo in tempo reale. Valuta in EUR.

Aggiungi a watchlist

137,62

+1,28

(+0,94%)

Alla chiusura: 04:24PM BST

Capitalizzazione	339,817B
Beta (5 anni mensile)	0,53
Rapporto PE (ttm)	21,95
EPS (ttm)	6,27
Prossima data utili	17 lug 2024
Rendimento e dividendo (futuro)	4,67 (3,42%)
Data ex dividendo	20 mag 2024
Stima target 1A	N/D

Tutte

GlobeNewswire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA